CBUS Cibus Inc

Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has expanded its intellectual property coverage for 10 gene editing and trait families. This intellectual property expansion over the last 6 months covers several areas including gene editing, productivity traits and quality traits, like high fiber wheat, strengthening the Company’s patent coverage in geographies including, but not limited to, Europe (EPO), Asia, Latin America, Canada, and the United States.

Cibus is a leader in the development of complex gene edited traits in plants like Pod Shatter Reduction in Canola and Herbicide Tolerance in Rice. The Company’s plant trait intellectual property is developed using its Rapid Trait Development System (RTDS®) including Gene Repair Oligonucleotides (GRON) and Transcription activator-like effector nuclease (TALEN) technology.

Greg Gocal, PhD, Co-Founder, Executive Vice President and Chief Scientific Officer at Cibus, commented, “The development of our intellectual property is foundational to our strategy and demonstrates our ability to edit complex traits across multiple crops. We are pleased with the recognition of the patent offices in many countries, who through their decisions have validated our know-how and ability to develop gene edited traits. It is also important that legacy traits received from our merger with Calyxt, Inc., like High Fiber Wheat and Improved Quality Alfalfa are a part of our intellectual property portfolio that includes the use of TALEN technologies.”

Noel Sauer, PhD, Senior Vice President of Research at Cibus, added, “Cibus’ technology team actively supports the Company’s commercial advancement efforts through protection of our trait and gene editing intellectual property. Importantly, protected traits can help accelerate our seed company customers’ timelines to farmer’s fields across global markets.”

The patents announced today solidify Cibus’ depth of intellectual property, driving development of its products and highlighting the strengths of its diversified portfolio of traits. Between Cibus and legacy Calyxt, Cibus now has rights to over 1,000 patents and patents applied for, including core original gene editing patents in agriculture.

About Cibus

Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the United Nations estimates cost the global economy approximately $300 billion annually. Cibus is not a seed company. It is a technology company that uses gene editing to develop and license traits to seed companies in exchange for royalties on seed sales. Cibus' focus is productivity traits for farmers for the major global row crops with large acreage such as canola, corn, rice, soybean, and wheat. Cibus is a technology leader in high throughput gene editing technology that enables Cibus to develop and commercialize plant traits at a fraction of the time and cost of conventional breeding. Cibus has developed a pipeline of five productivity traits including important traits for Pod Shatter Reduction, Sclerotinia (disease) resistance, and weed management. Its initial traits for Pod Shatter Reduction and weed management are in commercial development with leading seed companies such as Nuseed Americas Inc. in Canola as well as Nutrien Ltd. and Interoc S.A. in Rice in the United States and Latin America. Its other pipeline traits including Sclerotinia resistance are in advanced greenhouse and field trial stages.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "might," "plans," "predicts," "projects," "should," "targets," "will," or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the offering and the expected use of the proceeds from the offering. Completion of the offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

CIBUS CONTACTS:

INVESTOR RELATIONSKaren Troeberktroeber@cibus.com858-450-2636

MEDIA RELATIONSmedia@cibus.com(619) 849-6009

Colin Sanfordcolin@bioscribe.com203-918-4347